Seeking Alpha
 

Healthways, Inc. (HWAY)

- NASDAQ
  • Mon, Jan. 26, 9:14 AM
    | Comment!
  • Apr. 25, 2014, 12:47 PM
    | Comment!
  • Nov. 1, 2013, 5:47 PM
    | Comment!
  • Oct. 25, 2013, 3:12 PM
    • "We do expect meaningful changes in the HC marketplace, and we believe [the company] is well positioned to benefit. That is one reason we continue to cautiously recommend this stock," Dougherty's Brooks O'Neil says, regarding shares of Healthways (HWAY -28.8%).
    • Despite the cautious endorsement, O'Neil lowers the price target on the shares to $17 from $22, saying "it should be clear that the pace of change in HC can be painfully slow and it is often difficult to anticipate the specific nature of overall change because frequently there are puts and takes from various significant factors along the way."
    • For more on HWAY's quarter, see here.
    • Also: CC transcript (including Q&A between O'Neil and management).
    | Comment!
  • Oct. 25, 2013, 12:45 PM
    | 1 Comment
  • Oct. 25, 2013, 9:22 AM
    | 1 Comment
  • Oct. 25, 2013, 8:35 AM
    • It's shaping up to be a rough day for shares of Healthways (HWAY), which are down some 18% premarket, tracking Thursday's AH losses.
    • Q3 results missed estimates, revenue came in flat, and net income plunged 64% Y/Y to $1.8M.
    • HWAY cut its FY14 EPS and revenue guidance to -$0.10-0.04 and $665-675M, respectively, from $0.18-0.28/share on revenue of $710-750M. The Street expects $0.21/share on sales of $708.27M.
    • "The majority of the guidance change results from a much lower number of risk lives available in 2013 for our total population management services to health systems than was forecast in our previous guidance," CEO Ben Leedle says. (PR)
    | Comment!
  • Oct. 24, 2013, 5:45 PM
    | 4 Comments
  • Jul. 1, 2013, 10:30 AM
    Healthways (HWAY -1%) slips this morning on the announcement that it intends to privately offer $100M in convertible senior notes due 2018, with an option to purchase up to an additional $15M. The interest rate, conversion rate and other terms of the notes have yet to be determined.
    | Comment!
  • Jun. 21, 2013, 12:45 PM
    Midday top 10 gainers: ORMP +36%. USMD +28%. NVGN +20%. UAMY +19%. CYTK +19%. SPRD +17%. IMMU +17%. OSIS +13%. INPH +13%. HWAY +13%.
    Midday top 10 Losers: IDIX -34%. BPAX -18%. PMC -17%. EBIX -17%. ELP -15%. CLNT -15%. NBG -9%. ORCL -9%. EDMC -9%. DSS -9%.
    | 2 Comments
  • Jun. 3, 2013, 11:32 AM
    More on Piper Jaffray's upgrade of Healthways (HWAY +10.7%) which has the stock trading up double-digits: The company "will be a leader in the rapidly growing population health management segment," analyst Sean Wieland says, adding that "HWAY is the domain expert in population health management, yet has less than a 1% market share in the $1B per year opportunity" represented by Accountable Care Organizations.
    | Comment!
  • Apr. 19, 2013, 1:09 PM
    Midday top 10 gainers: VRTX +60%. NETE +33%. RH +21%. MCOX +18%. OSTK +17%. HWAY +17%. NVDQ +16%. ANAC +12%. LIVE +11%. CMG +10%.
    Midday top 10 losers: ACTG -25%. VIMC -15%. PRGX -14%. AIRM -14%. NSIT -12%. CNIT -11%. RMBS -10%. CRME -10%. DIT -9%. OSH -9%.
    | 1 Comment
  • Feb. 25, 2013, 12:24 PM
    Healthways (HWAY +4.1%) gets a boost from an upgrade to Outperform on valuation at William Blair earlier today, saying in a note to clients that the health-care provider has returned to a sustainable growth story.
    | Comment!
  • Dec. 11, 2012, 12:37 PM
    Healthways (HWAY -5.6%) slips after Citigroup initiated the shares today with a Sell and a $9 price target, saying that expectations for any margin improvement at the health-care provider are too high. Citi notes that contract losses, lower margins on new business, and less favorable rates on renewed contracts will wind up disappointing the Street consensus, and leave limited upside.
    | Comment!
  • Oct. 19, 2012, 10:43 AM
    Healthways (HWAY -11.3%) slips after its Q3 beat on its bottom line but came up short on revenue late yesterday. Net earnings fell 47% Y/Y as revenue was hurt by the continued wind-down of a contract with Cigna Corp. (CI). The company also lowered its full-year earnings estimates and narrowed its sales view due to higher operational costs as well as reduced revenue from two contracts that were renewed early.
    | Comment!
  • Jul. 25, 2012, 11:51 AM
    Healthways (HWAY) +19.2% after Q2 EPS of $0.15 beats by $0.06, and revenue edges up to $170.2M and comes in just above forecasts. Net profit falls to $5.06M from $5.78M. Earnings benefited from an earlier-than-expected recognition of performance-based fees. Continues "to expect substantially stronger earnings" for H2 than for H1. (PR)
    | Comment!
Visit Seeking Alpha's
HWAY vs. ETF Alternatives
Company Description
Healthways Inc provides comprehensive total population health management solutions that are designed to help people improve their well-being, thereby improving their health and productivity and reducing their health-related costs.